急性基底动脉闭塞的血管内治疗与药物治疗比较:一项随机临床试验的二次分析
本研究为ATTENTION试验的延长随访,纳入急性基底动脉闭塞12小时内的患者,比较血管内取栓与最佳药物治疗1年临床结局。330例有1年随访数据的患者中,取栓组mRS 0-3分比例高于对照组(44.6% vs 19.4%,校正率比2.23,95%CI 1.51-3.29),1年时取栓组mRS 0-1分比例较90天时增加,而对照组无增加,治疗获益扩大。
要点
- 取栓组1年mRS 0-3分比例44.6%,对照组19.4%,校正率比2.23(95%CI 1.51-3.29)。
- 取栓组1年死亡率45.5%,对照组63.9%;两组1年死亡率均高于90天时。
- 取栓组1年mRS 0-1分比例27.9%,较90天时19.9%增加,对照组无增加。
核心结论
- 在基底动脉闭塞发病12小时内的患者中,血管内取栓1年时良好结局(mRS 0-3分)的获益较90天时持续存在,优异结局(mRS 0-1分)的获益增强。
研究设计与样本
- 本研究为ATTENTION试验的延长随访,ATTENTION为多中心随机临床试验,在36个综合卒中中心开展。
- 患者纳入时间为2021年2月至2022年1月,1年随访至2023年4月。
- 纳入标准为估计症状发作12小时内的急性基底动脉闭塞患者。
- ATTENTION试验随机分组342例,其中330例(96.5%)有1年随访信息。
- 干预为血管内取栓(取栓组)对比最佳药物治疗(对照组)。
主要发现
- 330例有1年随访数据的患者中,227例(68.8%)为男性,平均(SD)年龄67.0(10.7)岁。
- 1年时mRS 0-3分:取栓组222例中99例(44.6%),对照组108例中21例(19.4%),校正率比2.23(95%CI 1.51-3.29)。
- 1年死亡率:取栓组222例中101例(45.5%),对照组108例中69例(63.9%);90天死亡率:取栓组226例中83例(36.7%),对照组114例中63例(55.3%)。
- 1年时mRS 0-1分:取栓组222例中62例(27.9%),对照组108例中9例(8.3%);90天时mRS 0-1分:取栓组226例中45例(19.9%),对照组114例中9例(7.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In several randomized clinical trials, endovascular thrombectomy led to better functional outcomes than conventional treatment at 90 days poststroke in patients with acute basilar artery occlusion. However, the long-term clinical outcomes of these patients have not been well delineated. OBJECTIVE: To evaluate 1-year clinical outcomes in patients with acute basilar artery occlusion following endovascular thrombectomy vs control. DESIGN, SETTING, AND PARTICIPANTS: This study is an extension of the ATTENTION trial, a multicenter, randomized clinical trial. Patients were included between February 2021 and January 2022, with 1-year follow-up through April 2023. This multicenter, population-based study was conducted at 36 comprehensive stroke sites. Patients with acute basilar artery occlusion within 12 hours of estimated symptom onset were included. Of the 342 patients randomized in the ATTENTION trial, 330 (96.5%) had 1-year follow-up information available. EXPOSURES: Endovascular thrombectomy (thrombectomy group) vs best medical treatment (control group). MAIN OUTCOMES AND MEASURES: The primary outcome was defined as a score of 0 to 3 on the modified Rankin Scale (mRS) at 1 year. Secondary outcomes were functional independence (mRS score 0-2), excellent outcome (mRS score 0-1), level of disability (distribution of all 7 mRS scores), mortality, and health-related quality of life at 1 year. RESULTS: Among 330 patients who had 1-year follow-up data, 227 (68.8%) were male, and the mean (SD) age was 67.0 (10.7) years. An mRS score 0 to 3 at 1 year was achieved by 99 of 222 patients (44.6%) in the thrombectomy group and 21 of 108 (19.4%) in the control group (adjusted rate ratio, 2.23; 95% CI, 1.51-3.29). Mortality at 1 year compared with 90 days was more frequent in both the thrombectomy group (101 of 222 [45.5%] vs 83 of 226 [36.7%]) and the control group (69 of 108 [63.9%] vs 63 of 114 [55.3%]). Excellent outcome (mRS score 0-1) at 1 year compared with 90 days increased in the thrombectomy group (62 of 222 [27.9%] vs 45 of 226 [19.9%]) but not in the control group (9 of 108 [8.3%] vs 9 of 114 [7.9%]) resulting in a magnified treatment benefit. CONCLUSIONS AND RELEVANCE: Among patients with basilar artery occlusion within 12 hours of onset, the benefits of endovascular thrombectomy at 1 year compared with 90 days were sustained for favorable (mRS score 0-3) outcome and enhanced for excellent (mRS score 0-1) outcome.
引用
- Li R, Tao C, Sun J, et al. Endovascular vs Medical Management of Acute Basilar Artery Occlusion: A Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 39186280. doi:10.1001/jamaneurol.2024.2652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。